Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

(2016) Emmanuel Seront et al.   BJU INTERNATIONAL

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma

(2016) R. L. Ross et al.   BMC CANCER

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition

(2016) Pau Castel et al.   CANCER CELL

CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1

(2016) Anuja Sathe et al.   JOURNAL OF UROLOGY

Genentech's PD-L1 agent approved for bladder cancer

(2016) Mark Ratner   NATURE BIOTECHNOLOGY

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

(2015) Carlotta Costa et al.   CANCER CELL

Drugging PI3K in cancer: refining targets and therapeutic strategies

(2015) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Targeting the translation machinery in cancer

(2015) Mamatha Bhat et al.   NATURE REVIEWS DRUG DISCOVERY

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

(2015) Günter Niegisch et al.   ONCOLOGY

Architecture of human mTOR complex 1

(2015) C. H. S. Aylett et al.   SCIENCE

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

(2015) Bipasha Mukherjee et al.   NEOPLASIA

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy

(2014) A Sathe et al.   BRITISH JOURNAL OF CANCER

The chick embryo chorioallantoic membrane as a model for tumor biology

(2014) Domenico Ribatti   EXPERIMENTAL CELL RESEARCH

Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance

(2014) E. Rozengurt et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Making new contacts: the mTOR network in metabolism and signalling crosstalk

(2014) Mitsugu Shimobayashi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Phase II study of everolimus in metastatic urothelial cancer

(2013) Matthew I. Milowsky et al.   BJU INTERNATIONAL

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

(2012) E. Seront et al.   ANNALS OF ONCOLOGY

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

(2012) Irene Brana et al.   BMC Medicine

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance

(2011) Holger Gerullis et al.   ANTI-CANCER DRUGS

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

(2011) Roman Nawroth et al.   PLoS One

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1

(2010) Ayaz Najafov et al.   BIOCHEMICAL JOURNAL

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

(2010) Carlos García-Echeverría   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition

(2010) Calvin K. Yip et al.   MOLECULAR CELL

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Key factors in mTOR regulation

(2009) Xiaochun Bai et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

DNA-dependent Protein Kinase-mediated Phosphorylation of Protein Kinase B Requires a Specific Recognition Sequence in the C-terminal Hydrophobic Motif

(2009) Jongsun Park et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTOR signaling at a glance

(2009) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PI3K/Akt: getting it right matters

(2008) T F Franke   ONCOGENE